Revolution-Adjuvant Daraxonrasib vs SOC in resected PDAC (RASolute 304) - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
[RMC-6236-304] RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Principal Investigator
Niharika B. Mettu, MD, PhD
Medical Oncologist
Protocol Number
IRB:
PRO00119103
NCT:
NCT07252232
Phase
Phase III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment